FDA Accepts Review of Formycon Keytruda Biosimilar Application
Formycon AG (XETR:FYB) announced that the U.S. Food and Drug Administration has accepted for review its Biologics License Application for FYB206, a proposed biosimilar to the cancer drug Keytruda. The filing acceptance triggers a milestone payment from licensing partner Zydus, which will handle commercialization of the drug candidate across the United States and Canada while sharing gross profits with Formycon.
The review acceptance marks an important regulatory step in Formycon's development of oncology biosimilars. FYB206 was advanced without requiring a Phase III efficacy trial, reducing development timelines and costs in alignment with draft guidance from regulators. The reference drug Keytruda generated $31.7 billion in global sales during 2025, representing a large market for potential biosimilar competition. Formycon shares rose 2.10% to 19.46 EUR following the update.
Investors will monitor the regulatory review process toward a target decision date in the third quarter of 2027 under Biosimilar User Fee Act timelines. Key factors ahead include resolution of intellectual property and commercial launch preparation by partner Zydus in North America.
Key points
- The FDA accepted Formycon AG's application for review of FYB206, a proposed Keytruda biosimilar.
- Formycon received a milestone payment from licensing partner Zydus following the application acceptance.
- Zydus will commercialize FYB206 in the U.S. and Canada under a gross profit sharing arrangement.
- Development did not require a Phase III efficacy trial, lowering costs and accelerating timelines.
- An FDA regulatory decision is expected in the third quarter of 2027 under BsUFA timelines.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
When is the FDA decision expected for Formycon's Keytruda biosimilar?
The FDA is expected to make a regulatory decision on Formycon's FYB206 application in the third quarter of 2027 under Biosimilar User Fee Act timelines.
Who is partnering with Formycon to commercialize FYB206 in North America?
Zydus holds commercialization rights for FYB206 in the U.S. and Canada. Formycon participates through a gross profit revenue-sharing structure and receives milestone payments under the licensing deal.
Did FYB206 require a Phase III clinical trial for FDA submission?
No Phase III efficacy trial was conducted for FYB206, aligning with FDA draft guidance and helping to reduce development time and costs.